Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer

od Leary, Alexandra, Le Tourneau, Christophe, Varga, Andrea, Sablin, Marie-Paule, Gomez-Roca, Carlos, Guilbaud, Nicolas, Petain, Aurelie, Pavlyuk, Mariya, Delord, Jean-Pierre
Wydane w Invest New Drugs (2018)

Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma: post‐hoc analyses from a phase III trial

od Pettengell, Ruth, Sebban, Catherine, Zinzani, Pier Luigi, Derigs, Hans Gunter, Kravchenko, Sergey, Singer, Jack W., Theocharous, Panteli, Wang, Lixia, Pavlyuk, Mariya, Makhloufi, Kahina M., Coiffier, Bertrand
Wydane w Br J Haematol (2016)

Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory...

od Fouquet, Guillemette, Guidez, Stéphanie, Richez, Valentine, Stoppa, Anne-Marie, Le Tourneau, Christophe, Macro, Margaret, Gruchet, Cécile, Bobin, Arthur, Moya, Niels, Syshenko, Thomas, Sabirou, Florence, Levy, Anthony, Franques, Paul, Gardeney, Hélène, Karlin, Lionel, Benboubker, Lotfi, Ouali, Monia, Vedovato, Jean-Claude, Ferre, Pierre, Pavlyuk, Mariya, Attal, Michel, Facon, Thierry, Leleu, Xavier
Wydane w Oncotarget (2018)